Global Drugs Based on CAR T-cell Market Growth (Status and Outlook) 2022-2028
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Drugs Based on CAR T-cell Market Size 2017-2028
- 2.1.2 Drugs Based on CAR T-cell Market Size CAGR by Region 2017 VS 2022 VS 2028
- 2.2 Drugs Based on CAR T-cell Segment by Type
- 2.2.1 CD19-targeted
- 2.2.2 BCMA-targeted
- 2.3 Drugs Based on CAR T-cell Market Size by Type
- 2.3.1 Drugs Based on CAR T-cell Market Size CAGR by Type (2017 VS 2022 VS 2028)
- 2.3.2 Global Drugs Based on CAR T-cell Market Size Market Share by Type (2017-2022)
- 2.4 Drugs Based on CAR T-cell Segment by Application
- 2.4.1 Lymphoma
- 2.4.2 Multiple Myeloma
- 2.5 Drugs Based on CAR T-cell Market Size by Application
- 2.5.1 Drugs Based on CAR T-cell Market Size CAGR by Application (2017 VS 2022 VS 2028)
- 2.5.2 Global Drugs Based on CAR T-cell Market Size Market Share by Application (2017-2022)
3 Drugs Based on CAR T-cell Market Size by Player
- 3.1 Drugs Based on CAR T-cell Market Size Market Share by Players
- 3.1.1 Global Drugs Based on CAR T-cell Revenue by Players (2020-2022)
- 3.1.2 Global Drugs Based on CAR T-cell Revenue Market Share by Players (2020-2022)
- 3.2 Global Drugs Based on CAR T-cell Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Drugs Based on CAR T-cell by Regions
- 4.1 Drugs Based on CAR T-cell Market Size by Regions (2017-2022)
- 4.2 Americas Drugs Based on CAR T-cell Market Size Growth (2017-2022)
- 4.3 APAC Drugs Based on CAR T-cell Market Size Growth (2017-2022)
- 4.4 Europe Drugs Based on CAR T-cell Market Size Growth (2017-2022)
- 4.5 Middle East & Africa Drugs Based on CAR T-cell Market Size Growth (2017-2022)
5 Americas
- 5.1 Americas Drugs Based on CAR T-cell Market Size by Country (2017-2022)
- 5.2 Americas Drugs Based on CAR T-cell Market Size by Type (2017-2022)
- 5.3 Americas Drugs Based on CAR T-cell Market Size by Application (2017-2022)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Drugs Based on CAR T-cell Market Size by Region (2017-2022)
- 6.2 APAC Drugs Based on CAR T-cell Market Size by Type (2017-2022)
- 6.3 APAC Drugs Based on CAR T-cell Market Size by Application (2017-2022)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Drugs Based on CAR T-cell by Country (2017-2022)
- 7.2 Europe Drugs Based on CAR T-cell Market Size by Type (2017-2022)
- 7.3 Europe Drugs Based on CAR T-cell Market Size by Application (2017-2022)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Drugs Based on CAR T-cell by Region (2017-2022)
- 8.2 Middle East & Africa Drugs Based on CAR T-cell Market Size by Type (2017-2022)
- 8.3 Middle East & Africa Drugs Based on CAR T-cell Market Size by Application (2017-2022)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Drugs Based on CAR T-cell Market Forecast
- 10.1 Global Drugs Based on CAR T-cell Forecast by Regions (2023-2028)
- 10.1.1 Global Drugs Based on CAR T-cell Forecast by Regions (2023-2028)
- 10.1.2 Americas Drugs Based on CAR T-cell Forecast
- 10.1.3 APAC Drugs Based on CAR T-cell Forecast
- 10.1.4 Europe Drugs Based on CAR T-cell Forecast
- 10.1.5 Middle East & Africa Drugs Based on CAR T-cell Forecast
- 10.2 Americas Drugs Based on CAR T-cell Forecast by Country (2023-2028)
- 10.2.1 United States Drugs Based on CAR T-cell Market Forecast
- 10.2.2 Canada Drugs Based on CAR T-cell Market Forecast
- 10.2.3 Mexico Drugs Based on CAR T-cell Market Forecast
- 10.2.4 Brazil Drugs Based on CAR T-cell Market Forecast
- 10.3 APAC Drugs Based on CAR T-cell Forecast by Region (2023-2028)
- 10.3.1 China Drugs Based on CAR T-cell Market Forecast
- 10.3.2 Japan Drugs Based on CAR T-cell Market Forecast
- 10.3.3 Korea Drugs Based on CAR T-cell Market Forecast
- 10.3.4 Southeast Asia Drugs Based on CAR T-cell Market Forecast
- 10.3.5 India Drugs Based on CAR T-cell Market Forecast
- 10.3.6 Australia Drugs Based on CAR T-cell Market Forecast
- 10.4 Europe Drugs Based on CAR T-cell Forecast by Country (2023-2028)
- 10.4.1 Germany Drugs Based on CAR T-cell Market Forecast
- 10.4.2 France Drugs Based on CAR T-cell Market Forecast
- 10.4.3 UK Drugs Based on CAR T-cell Market Forecast
- 10.4.4 Italy Drugs Based on CAR T-cell Market Forecast
- 10.4.5 Russia Drugs Based on CAR T-cell Market Forecast
- 10.5 Middle East & Africa Drugs Based on CAR T-cell Forecast by Region (2023-2028)
- 10.5.1 Egypt Drugs Based on CAR T-cell Market Forecast
- 10.5.2 South Africa Drugs Based on CAR T-cell Market Forecast
- 10.5.3 Israel Drugs Based on CAR T-cell Market Forecast
- 10.5.4 Turkey Drugs Based on CAR T-cell Market Forecast
- 10.5.5 GCC Countries Drugs Based on CAR T-cell Market Forecast
- 10.6 Global Drugs Based on CAR T-cell Forecast by Type (2023-2028)
- 10.7 Global Drugs Based on CAR T-cell Forecast by Application (2023-2028)
11 Key Players Analysis
- 11.1 Novartis
- 11.1.1 Novartis Company Information
- 11.1.2 Novartis Drugs Based on CAR T-cell Product Offered
- 11.1.3 Novartis Drugs Based on CAR T-cell Revenue, Gross Margin and Market Share (2020-2022)
- 11.1.4 Novartis Main Business Overview
- 11.1.5 Novartis Latest Developments
- 11.2 Gilead Sciences
- 11.2.1 Gilead Sciences Company Information
- 11.2.2 Gilead Sciences Drugs Based on CAR T-cell Product Offered
- 11.2.3 Gilead Sciences Drugs Based on CAR T-cell Revenue, Gross Margin and Market Share (2020-2022)
- 11.2.4 Gilead Sciences Main Business Overview
- 11.2.5 Gilead Sciences Latest Developments
- 11.3 Bristol-Myers Squibb
- 11.3.1 Bristol-Myers Squibb Company Information
- 11.3.2 Bristol-Myers Squibb Drugs Based on CAR T-cell Product Offered
- 11.3.3 Bristol-Myers Squibb Drugs Based on CAR T-cell Revenue, Gross Margin and Market Share (2020-2022)
- 11.3.4 Bristol-Myers Squibb Main Business Overview
- 11.3.5 Bristol-Myers Squibb Latest Developments
- 11.4 J & J
- 11.4.1 J & J Company Information
- 11.4.2 J & J Drugs Based on CAR T-cell Product Offered
- 11.4.3 J & J Drugs Based on CAR T-cell Revenue, Gross Margin and Market Share (2020-2022)
- 11.4.4 J & J Main Business Overview
- 11.4.5 J & J Latest Developments
- 11.5 JW Therapeutics
- 11.5.1 JW Therapeutics Company Information
- 11.5.2 JW Therapeutics Drugs Based on CAR T-cell Product Offered
- 11.5.3 JW Therapeutics Drugs Based on CAR T-cell Revenue, Gross Margin and Market Share (2020-2022)
- 11.5.4 JW Therapeutics Main Business Overview
- 11.5.5 JW Therapeutics Latest Developments
- 11.6 FOSUNKite
- 11.6.1 FOSUNKite Company Information
- 11.6.2 FOSUNKite Drugs Based on CAR T-cell Product Offered
- 11.6.3 FOSUNKite Drugs Based on CAR T-cell Revenue, Gross Margin and Market Share (2020-2022)
- 11.6.4 FOSUNKite Main Business Overview
- 11.6.5 FOSUNKite Latest Developments
12 Research Findings and Conclusion
As the global economy mends, the 2021 growth of Drugs Based on CAR T-cell will have significant change from previous year. According to our (LP Information) latest study, the global Drugs Based on CAR T-cell market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Drugs Based on CAR T-cell market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Drugs Based on CAR T-cell market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Drugs Based on CAR T-cell market, reaching US$ million by the year 2028. As for the Europe Drugs Based on CAR T-cell landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Drugs Based on CAR T-cell players cover Novartis, Gilead Sciences, Bristol-Myers Squibb, and J & J, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Drugs Based on CAR T-cell market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
CD19-targeted
BCMA-targeted
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Lymphoma
Multiple Myeloma
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Novartis
Gilead Sciences
Bristol-Myers Squibb
J & J
JW Therapeutics
FOSUNKite